Uses of Oubapentin

Oubapentin medicine has the main ingredient is Pregabalin with a content of 150 mg, prepared in the form of hard capsules.
Pregabalin is an analog of gamma-aminobutyric acid (GABA). After oral administration, Pregabalin binds to a subunit of the calcium potential portal channel in the CNS. Evidence from animal models of nerve damage shows that pregabalin reduces the release of calcium-dependent nociceptors in the spinal cord, possibly by blocking calcium transport and decreasing calcium influx. ; In addition, this model also shows that the analgesic activity of pregabalin may be indirectly through interaction with the parasympathetic nerve pathways transmitted by the hormones noradrenalin and serotonin.
From there, the drug has the effect of reducing nerve conduction and helping to reduce pain caused by nerve factors.

Oubapentin is indicated for use in the following cases:
Treatment of pain due to neurogenic causes in adults. Treatment of epilepsy: Pregabalin is indicated for the adjuvant treatment of partial seizures with or without secondary generalization in adults. Treatment of generalized anxiety disorder in adults Treatment of fibromyalgia.

Oubapentin can be taken with or without food.
Adults: The commonly used dose range is 150 mg to 600 mg per day in 2-3 divided doses. Neuropathic pain: Treatment with Oubapentin may be initiated at a dose of 150mg daily. Depending on the patient's response and individual tolerability, the dose may be increased to 300 mg/day over an interval of 3-7 days, and if necessary you may increase to a maximum dose of 600 mg/day. mg/day after approximately 7 days of additional treatment. Fibromyalgia: The usual dose for most patients is between 300 mg and 450 mg/day orally in 2 divided doses. Some patients may be better off with higher doses of 600 mg/day. A dose should be initiated at 75 mg twice daily (ie 150 mg/day) and may be increased to 150 mg twice daily (ie 300 mg/day) within 1 week depending on efficacy. results and tolerability. For patients who do not respond adequately to 300 mg/day, the dose may be increased to 225 mg twice daily (ie 450 mg/day). If necessary, in some patients, depending on individual response and tolerability, the dose may be increased to a maximum of 600 mg/day after an additional week of 450 mg/day treatment. Menopause: Treatment with pregabalin can be initiated at a dose of approximately 150 mg per day. Depending on the individual patient, the dose may be increased to 300 mg/day after 1 week. May increase to a maximum dose of 600 mg/day after 1 additional week of treatment. Generalized Anxiety Disorder: The usual dose range is 150 mg - 600 mg per day and is given in two or three divided doses. The patient's treatment needs should be reassessed regularly. Treatment with pregabalin can be initiated at a dose of 150 mg/day. Based on individual patient response and tolerability, the dose may be increased to 300 mg/day after 1 week of treatment. After another week of treatment, the dose may be increased to 450 mg/day. The dose may be increased to a maximum of 600 mg/day after 1 additional week of treatment. If pregabalin must be discontinued, the dose should be reduced gradually over a minimum of 1 week.
Children: Safety and effectiveness have not been established in children under 12 years of age, adolescents 12-17 years of age. Elderly (over 65 years of age): Elderly patients taking this drug may require a reduction in the dose of pregabalin due to decreased renal function. Renal Impairment: Dosage adjustment is required, dose reduction in patients with impaired renal function must be based on creatinine clearance (CLcr).

When using Oubapentin you may experience unwanted effects, including:
Common
Whole body: Peripheral edema, abnormal gait, frequent falls, feeling drunk, fatigue, weight gain . Respiratory: Nasopharyngitis. Neurological: Dizziness, often feeling sleepy or insomnia, headache, dizziness, euphoria, confusion, irritability, disorientation, decreased libido, amnesia, memory impairment , attention disorder, sensory disturbance, sedation, balance disorder, coma. Eyes: Blurry vision and possible double vision. Gastrointestinal: Nausea, constipation or diarrhea, flatulence, abdominal distension, dry mouth. Heart: Cardiac arrhythmia. Musculoskeletal: Cramps, joint pain, back pain, limb pain, cervical spasm. Uncommon side effects:
Body as a whole: Generalized edema, facial edema, chest tightness, pain, drug fever, thirst, chills, weakness. Cardiac: Tachycardia, first degree atrioventricular block, sinus bradycardia, congestive heart failure. Blood vessels: Hypotension or hypertension, hot flashes, flushing. Shortness of breath, nosebleed, cough, stuffy nose, rhinitis, snoring, dry nose. Digestive: Gastroesophageal reflux disease (GERD), increased salivation, decreased mouth sensation. Papular rash, urticaria, pruritus. Musculoskeletal and connective tissue: Swelling, joint pain, muscle pain, muscle twitching, neck pain, muscle stiffness. Kidney and urinary tract: Urinary incontinence or difficulty urinating. Other: Sexual dysfunction, delayed ejaculation, dysmenorrhea, breast pain; Blood creatine phosphokinase increased, blood glucose increased, platelet count decreased, blood creatinine increased, blood potassium decreased. When experiencing side effects of the drug while taking the drug, you need to stop using this medicine and notify your doctor or you need to go to the nearest medical facility for timely treatment.

Before using the drug you need to read the drug information carefully, tell your doctor if you are allergic to the drug or to other agents. Do not take this medicine if you have a cold with Pregabalin or any of its ingredients. Use with caution if you have rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption patients should not take this medicine. Some patients with diabetes may experience weight gain while taking pregabalin, sometimes requiring an adjustment in the use of hypoglycemic agents. Oubapentin should be discontinued immediately if severe allergic symptoms such as angioedema, such as facial edema, perioral edema, or upper respiratory tract edema occur. Treatment with Pregabalin often results in dizziness and drowsiness, decreased vision, this can increase the risk of traumatic accidents in the elderly or in traffic. There have been post-marketing reports of loss of consciousness, confusion, and mental decline. There are no adequate data on discontinuation of pregabalin and other antiepileptic drugs to switch to pregabalin monotherapy, once seizures have been controlled with combination therapy. . During short-term and long-term treatment with Pregabalin, after discontinuation of the drug, a withdrawal syndrome has been observed in some patients. Reported effects include insomnia, headache, nausea, anxiety, sweating, and diarrhea. Therefore, to help reduce this risk, it is necessary to reduce the dose before stopping the drug. Avoid abrupt discontinuation, especially when taking high doses and for a long time. As with any drug that acts on the central nervous system, the patient should be carefully evaluated for a history of drug abuse and carefully observed for signs of misuse or abuse of pregabalin. Ensure that patients adhere to medication use to avoid abuse and misuse, increasing the risk of side effects and reducing the effectiveness of the drug. Use with caution in patients with kidney and cardiovascular disease: When taking the drug can affect kidney function and some reports that kidney function improves after you stop or reduce the dose of pregabalin; Due to limited data on the use of the drug in patients with severe congestive heart failure, pregabalin should be used with caution in these patients. Pregnancy: Oubapentin should not be used while you are pregnant unless the potential benefit to the mother outweighs the potential risk to the fetus. An additional effective method of contraception must be used in women of childbearing age while taking pregabalin. If you don't know what is right for you, talk to your obstetrician. Lactation: Pregabalin is excreted in breast milk in lactating women. Because the safety of pregabalin in neonates is currently unknown, breastfeeding during pregabalin treatment is not recommended. When deciding whether to discontinue breastfeeding, the benefits of breastfeeding for the infant should be weighed against the benefits of drug therapy for the mother.

Pregabalin may interfere with the nervous system effects of ethanol and lorazepam. Pregabalin may add to the disturbances in cognition and overall motor function caused by oxycodone. There have been reports of an increased risk of respiratory depression and coma in patients receiving pregabalin and other CNS depressants. Events associated with decreased lower gastrointestinal function such as intestinal obstruction, paralytic ileus, and constipation have been observed when pregabalin is used with medicinal products that are potentially constipating, such as analgesics. opioid group. Above is the information about Oubapentin drug, this drug is a prescription drug to be used as directed by your doctor. Make sure to take the medicine exactly as prescribed to increase its effectiveness.